Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Device Stakeholders Debate Whether FDA Can, Or Should, Revoke 510(k)s

This article was originally published in The Gray Sheet

Executive Summary

FDA should have no reason to rescind 510(k) substantial equivalence decisions for marketed devices except in extreme cases of fraud, device industry lobbyists said in recent comments to FDA
Advertisement

Related Content

CDRH Drops Seven Divisive 510(k) Proposals; Congress Picks Some Up
ReGen Declines "Futile" 510(k) Rescission Hearing But Plans Legal Challenge
ReGen Declines "Futile" 510(k) Rescission Hearing But Plans Legal Challenge
Chart: More 510(k) Reform Fears: Condition of Clearance Studies, GMPs?
FDA Hints At Possible 510(k) Tweaks At Public Meeting
Do-Over? FDA Orders Look-Back At Knee Device 510(k) Review Process

Topics

Advertisement
UsernamePublicRestriction

Register

MT028666

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel